Analysts Set CureVac N.V. (NASDAQ:CVAC) Target Price at $6.83

Shares of CureVac N.V. (NASDAQ:CVAC) have been given a consensus recommendation of “Hold” by the six brokerages that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $6.8333.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of CureVac in a research report on Tuesday, December 16th.

CureVac Price Performance

CVAC opened at $4.66 on Thursday. CureVac has a one year low of $4.00 and a one year high of $4.68. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.70 and a quick ratio of 3.69. The company’s 50 day simple moving average is $4.67 and its 200-day simple moving average is $5.12. The stock has a market capitalization of $1.05 billion, a P/E ratio of 6.47 and a beta of 1.77.

CureVac (NASDAQ:CVAC) last posted its quarterly earnings data on Monday, November 24th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.07. CureVac had a net margin of 199.92% and a negative return on equity of 23.03%. The firm had revenue of $63.53 million during the quarter, compared to analysts’ expectations of $21.40 million. Sell-side analysts anticipate that CureVac will post 0.72 earnings per share for the current fiscal year.

Institutional Trading of CureVac

A number of institutional investors have recently bought and sold shares of CVAC. Leonteq Securities AG acquired a new position in shares of CureVac in the 4th quarter valued at $127,000. SG Americas Securities LLC bought a new stake in CureVac in the fourth quarter valued at about $79,000. Qube Research & Technologies Ltd lifted its stake in CureVac by 44.9% in the third quarter. Qube Research & Technologies Ltd now owns 1,712,737 shares of the company’s stock valued at $9,232,000 after buying an additional 530,686 shares during the period. Bank of America Corp DE boosted its holdings in CureVac by 364.4% during the third quarter. Bank of America Corp DE now owns 443,324 shares of the company’s stock worth $2,390,000 after buying an additional 347,854 shares during the last quarter. Finally, AQR Arbitrage LLC grew its position in shares of CureVac by 2,145.7% during the 3rd quarter. AQR Arbitrage LLC now owns 991,688 shares of the company’s stock worth $5,345,000 after buying an additional 947,529 shares during the period. Institutional investors and hedge funds own 17.26% of the company’s stock.

CureVac Company Profile

CureVac N.V. is a clinical-stage biopharmaceutical company that specializes in the research, development and commercialization of messenger RNA (mRNA)-based medicines and vaccines. Leveraging its proprietary mRNA platform, the company seeks to harness the body’s natural protein production processes to address a range of diseases, with particular emphasis on prophylactic vaccines for infectious diseases as well as therapeutic candidates in oncology. CureVac’s technology is designed to deliver optimized mRNA sequences for in vivo expression, aiming to improve stability, translational efficiency and immunogenicity compared with conventional approaches.

Founded in 2000 and headquartered in Tübingen, Germany, CureVac has built a pipeline spanning early- to late-stage clinical programs.